Connect Biopharma Holdings Limited (CNTB)
NASDAQ: CNTB · Real-Time Price · USD
2.995
+0.065 (2.22%)
At close: Apr 16, 2026, 4:00 PM EDT
2.990
-0.005 (-0.17%)
After-hours: Apr 16, 2026, 6:27 PM EDT
Company Description
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of inflammatory diseases in the United States.
The company’s lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is in Phase 3 studies for the treatment of inflammatory diseases such as atopic dermatitis and asthma.
Connect Biopharma Holdings Limited was founded in 2012 and is headquartered in San Diego, California.
Connect Biopharma Holdings Limited
| Country | United States |
| Founded | 2012 |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 64 |
| CEO | Barry Quart |
Contact Details
Address: 3580 CARMEL MOUNTAIN ROAD, SUITE 200 San Diego, California 92130 United States | |
| Phone | 858 727 1040 |
| Website | connectbiopharm.com |
Stock Details
| Ticker Symbol | CNTB |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 1835268 |
| CUSIP Number | G23549101 |
| ISIN Number | KYG235491019 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Barry D. Quart Pharm.D. | Chief Executive Officer and Director |
| David L. Szekeres J.D. | President |
| Jeff Cohn J.D. | General Counsel and Corporate Secretary |
| Sean T. Ristine | Vice President of Human Resources |
| Dr. Lei Sun Ph.D. | Vice President of Biologics and Head of CMC |
| Dr. Srikanth Pendyala M.D. | Senior Vice President of Clinical Development(Consultant) |
| Kimberly J. Manhard | Executive Vice President and Chief Development Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 14, 2026 | SCHEDULE 13G | Filing |
| Apr 1, 2026 | SCHEDULE 13D/A | Filing |
| Mar 31, 2026 | 10-K | Annual Report |
| Mar 31, 2026 | 8-K | Current Report |
| Mar 30, 2026 | 8-K | Current Report |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G/A | Filing |
| Feb 17, 2026 | SCHEDULE 13G | Filing |
| Dec 23, 2025 | 8-K | Current Report |
| Nov 28, 2025 | SCHEDULE 13G/A | Filing |